/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Company Overview We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the poten…
$14.05
$0.01 (-0.07%)
EOD Sep 18, 2026
Negative free cash flow of -$55M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$58M
▲ +19.0% YoY
Op. Margin
—
ROIC
-28.11%
▲ +11.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$53M
▼ -250.5% YoY
Op. Cash Flow (TTM)
-$53M
▼ -249.3% YoY
Net Debt
-$182M
Net Cash Position
Cash & Equiv.
$183M
Continue Research
SourceComputed from the 10-Q filed 6 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 7 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.